Executive Summary Commercial success in adult and pediatric neurology is rarely determined by clinical efficacy alone. Academic physicians, particularly those practicing within major neurological Centers of Excellence, evaluate therapies within a broader context that includes scientific credibility, institutional trust, implementation feasibility, long-term clinical value, and the commitment of the sponsoring company to advancing the disease state. Too often, biotechnology companies invest hundreds of millions of dollars generating clinical evidence while…
Full article
Full article available by request only.
Contact PharmaKonsult to request the complete opinion paper.